Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.

Li G, Zhang L, Chen E, Wang J, Jiang X, Chen JH, Wickman G, Amundson K, Bergqvist S, Zobel J, Buckman D, Baxi SM, Bender SL, Casperson GF, Hu-Lowe DD.

Cancer Res. 2010 Dec 15;70(24):10243-54. doi: 10.1158/0008-5472.CAN-10-1996. Erratum in: Cancer Res. 2011 Feb 15;71(4):1507.

2.

Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.

Ashraf SQ, Umana P, Mössner E, Ntouroupi T, Brünker P, Schmidt C, Wilding JL, Mortensen NJ, Bodmer WF.

Br J Cancer. 2009 Nov 17;101(10):1758-68. doi: 10.1038/sj.bjc.6605355.

3.

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.

Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, Hanna NN, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE.

Eur J Cancer. 2013 Oct;49(15):3344-52. doi: 10.1016/j.ejca.2013.06.009.

PMID:
23871153
4.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S.

Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517.

5.

Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.

Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P.

MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.

6.

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.

Cancer Res. 2007 Sep 15;67(18):8882-90. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692. Vijh, Sujata [added].

7.

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.

Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US.

Blood. 2012 Mar 1;119(9):2074-82. doi: 10.1182/blood-2011-06-364521.

8.

Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.

Namboodiri AM, Pandey JP.

Clin Exp Immunol. 2011 Dec;166(3):361-5. doi: 10.1111/j.1365-2249.2011.04477.x.

9.

Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.

Kumpel BM, Beliard R, Brossard Y, Edelman L, de Haas M, Jackson DJ, Kooyman P, Ligthart PC, Monchâtre E, Overbeeke MA, Puillandre P, de Romeuf C, Wilkes AM.

Transfus Clin Biol. 2002 Jan;9(1):45-53.

PMID:
11889899
10.

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.

Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC.

MAbs. 2014 May-Jun;6(3):749-55. doi: 10.4161/mabs.28282.

11.

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.

Liu Z, Gunasekaran K, Wang W, Razinkov V, Sekirov L, Leng E, Sweet H, Foltz I, Howard M, Rousseau AM, Kozlosky C, Fanslow W, Yan W.

J Biol Chem. 2014 Feb 7;289(6):3571-90. doi: 10.1074/jbc.M113.513366.

12.

An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.

Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ.

MAbs. 2015;7(3):494-504. doi: 10.1080/19420862.2015.1022692.

13.

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.

Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035.

PMID:
23872058
14.

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ.

Cancer Res. 2003 Sep 1;63(17):5595-600.

15.

IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.

Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X.

Hum Antibodies. 2010;19(4):89-99. doi: 10.3233/HAB-2010-0232.

PMID:
21178280
16.

Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.

Srivastava S, Pelloso D, Feng H, Voiles L, Lewis D, Haskova Z, Whitacre M, Trulli S, Chen YJ, Toso J, Jonak ZL, Chang HC, Robertson MJ.

Cancer Immunol Immunother. 2013 Jun;62(6):1073-82. doi: 10.1007/s00262-013-1403-0.

17.

High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS.

Mol Immunol. 2006 Mar;43(8):1183-93.

PMID:
16102830
18.

A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.

Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V.

J Transl Med. 2007 Nov 27;5:61.

19.

Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.

Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F, Surowy T.

J Immunol Methods. 2014 Dec 1;414:69-81. doi: 10.1016/j.jim.2014.07.010.

PMID:
25086226
20.

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.

Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE.

Blood. 2009 Apr 16;113(16):3735-43. doi: 10.1182/blood-2008-10-182048.

Supplemental Content

Support Center